Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: A critical and systematic review of the literature in the development of an HPV dynamic transmission model

BMC Infectious Diseases

Volumn 9, Issue , 2009, Pages

  Insinga, Ralph P ^a   Dasbach, Erik J ^a   Elbasha, Elamin H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; IMIQUIMOD; WART VIRUS VACCINE;

CANCER LOCALIZATION; CLINICAL PRACTICE; CLINICAL TRIAL; COLPOSCOPY; CONDYLOMA ACUMINATUM; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; ERADICATION THERAPY; HELP SEEKING BEHAVIOR; HUMAN; HYSTERECTOMY; INFECTION CONTROL; LOOP ELETROSURGICAL EXCISION PROCEDURE; PAPANICOLAOU TEST; PATIENT ATTITUDE; REMISSION; REVIEW; SENSITIVITY AND SPECIFICITY; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; UNITED STATES; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION; UTERINE CERVIX CYTOLOGY; VIROGENESIS; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS TRANSMISSION; VIRUS TYPING; WART VIRUS; AGE; BIOLOGICAL MODEL; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; TIME; UTERINE CERVIX TUMOR;

AGE FACTORS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CONDYLOMATA ACUMINATA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MODELS, BIOLOGICAL; PAPILLOMAVIRUS INFECTIONS; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 69049115282     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-9-119     Document Type: Review

References (133)

1. Parkin DM Bray F Ferlay J Pisani P Global cancer statistics, 2002 CA Cancer J Clin 2005, 55:74-108. 15761078 10.3322/canjclin.55.2.74
2. Walboomers JM Jacobs MV Manos MM et al Human papillomavirus is a necessary cause of invasive cervical cancer worldwide J Pathol 1999, 189:12-19. 10451482 10.1002/ (SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
3. Carter JJ Madeleine MM Shera K et al Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites Cancer Res 2001, 61:1934-1940. 11280749
4. Gillison ML Koch WM Capone RB et al Evidence for a causal association between human papillomavirus and a subset of head and neck cancers J Natl Cancer Inst 2000, 92:709-720. 10793107 10.1093/jnci/92.9.709
5. Koutsky L Epidemiology of genital human papillomavirus infection Am J Med 1997, 102:3-8. 9217656 10.1016/S0002-9343(97)00177-0
6. Wiatrak BJ Overview of recurrent respiratory papillomatosis Curr Opin Otolaryngol Head Neck Surg 2003, 11:433-441. 14631175 10.1097/ 00020840-200312000-00005
7. Goldie SJ Kohli M Grima D et al Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine J Natl Cancer Inst 2004, 96:604-615. 15100338
8. Kulasingam SL Myers ER Potential health and economic impact of adding a human papillomavirus vaccine to screening programs JAMA 2003, 290:781-789. 12915431 10.1001/jama.290.6.781
9. Sanders GD Taira AV Cost-effectiveness of a potential vaccine for human papillomavirus Emerg Infect Dis 2003, 9:37-48. 12533280
10. Dasbach EJ Elbasha EH Insinga RP Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease Epidemiol Rev 2006, 28:88-100. 16740585 10.1093/epirev/mxj006
11. Brown AD Garber AM Cost-effectiveness of 3 methods to enhance the sensitivity of Papanicolaou testing JAMA 1999, 281:347-353. 9929088 10.1001/jama.281.4.347
12. Kulasingam SL Hughes JP Kiviat NB et al Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral JAMA 2002, 288:1749-1757. 12365959 10.1001/jama.288.14.1749
13. Mandelblatt JS Lawrence WF Womack SM et al Benefits and costs of using HPV testing to screen for cervical cancer JAMA 2002, 287:2372-2381. 11988058 10.1001/jama.287.18.2372
14. Elbasha EH Dasbach EJ Insinga RP Model for assessing human papillomavirus vaccination strategies Emerg Infect Dis 2007, 13:28-41. 17370513
15. Barnabas RV Laukkanen P Koskela P Kontula O Lehtinen M Garnett GP Epidemiology of HPV 16 and Cervical Cancer in Finland and the Potential Impact of Vaccination: Mathematical Modelling Analyses PLoS Med 2006, 3:e138. 16573364 10.1371/journal.pmed.0030138 1434486
16. Clifford GM Smith JS Plummer M Munoz N Franceschi S Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis Br J Cancer 2003, 88:63-73. 12556961 10.1038/sj.bjc.6600688
17. Brown DR Schroeder JM Bryan JT Stoler MH Fife KH Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients J Clin Microbiol 1999, 37:3316-3322. 85555 10488198
18. Greer CE Wheeler CM Ladner MB et al Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts J Clin Microbiol 1995, 33:2058-2063. 228335 7559948
19. Harper DM Franco EL Wheeler C et al Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial Lancet 2004, 364:1757-1765. 15541448 10.1016/S0140-6736(04)17398-4
20. Villa LL Costa RL Petta CA et al Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial Lancet Oncol 2005, 6:271-278. 15863374 10.1016/ S1470-2045(05)70101-7
21. Kim JJ Wright TC Goldie SJ Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance JAMA 2002, 287:2382-2390. 11988059 10.1001/jama.287.18.2382
22. Myers ER McCrory DC Nanda K Bastian L Matchar DB Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis Am J Epidemiol 2000, 151:1158-1171. 10905528
23. Berkhof J de Bruijne MC Zielinski GD Meijer CJ Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands Int J Cancer 2005, 115:268-275. 15688404 10.1002/ijc.20846
24. Canfell K Barnabas R Patnick J Beral V The predicted effect of changes in cervical screening practice in the UK: Results from a modelling study Br J Cancer 2004, 91:530-536. 15266332 10.1038/sj.bjc.6602002
25. Fahs MC Mandelblatt J Schechter C Muller C Cost effectiveness of cervical cancer screening for the elderly Ann Intern Med 1992, 117:520-527. 1503355
26. Goldie SJ Grima D Kohli M Wright TC Weinstein M Franco E A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine Int J Cancer 2003, 106:896-904. 12918067 10.1002/ijc.11334
27. Cantor SB Atkinson EN Cardenas-Turanzas M Benedet JL Follen M MacAulay C Natural history of cervical intraepithelial neoplasia: A meta-analysis Acta Cytol 2005, 49:405-415. 16124170
28. Melnikow J Nuovo J Willan AR Chan BK Howell LP Natural history of cervical squamous intraepithelial lesions: A meta-analysis Obstet Gynecol 1998, 92:727-735. 9764690 10.1016/S0029-7844(98)00245-2
29. Ostor AG Natural history of cervical intraepithelial neoplasia: A critical review Int J Gynecol Pathol 1993, 12:186-192. 8463044 10.1097/ 00004347-199304000-00018
30. Syrjanen KJ Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV) Eur J Obstet Gynecol Reprod Biol 1996, 65:45-53. 8706956 10.1016/ 0028-2243(95)02303-A
31. Woodman CB Rollason T Ellis J Tierney R Wilson S Young L Human papillomavirus infection and risk of progression of epithelial abnormalities of the cervix Br J Cancer 1996, 73:553-556 8595174
32. Solomon D Schiffman M Tarone R Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial J Natl Cancer Inst 2001, 93:293-299. 11181776 10.1093/jnci/93.4.293
33. Chenoy R Billingham L Irani S Rollason TP Luesley DM Jordan JA The effect of directed biopsy on the atypical cervical transformation zone: assessed by digital imaging colposcopy Br J Obstet Gynaecol 1996, 103:457-462. 8624320
34. Woodman CB Collins S A critique of cohort studies examining the role of human papillomavirus infection in cervical neoplasia BJOG 2002, 109:1311-1318. 12504964 10.1046/j.1471-0528.2002.02008.x
35. Syrjanen K Yliskoski M Kataja V et al Prevalence of genital human papillomavirus infections in a mass-screened Finnish female population aged 20-65 years Int J STD AIDS 1990, 1:410-415. 1965568
36. Koutsky LA Holmes KK Critchlow CW et al A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection N Engl J Med 1992, 327:1272-1278. 1328880
37. Nuovo GJ Blanco JS Leipzig S Smith D Human papillomavirus detection in cervical lesions nondiagnostic for cervical intraepithelial neoplasia: correlation with Papanicolaou smear, colposcopy, and occurrence of cervical intraepithelial neoplasia Obstet Gynecol 1990, 75:1006-1011. 2160630
38. Jacobs MV Snijders PJ Voorhorst FJ et al Reliable high risk HPV DNA testing by polymerase chain reaction: An intermethod and intramethod comparison J Clin Pathol 1999, 52:498-503. 10605401 10.1136/jcp.52.7.498 501489
39. Kosel S Burggraf S Mommsen J Engelhardt W Olgemoller B Type-specific detection of human papillomaviruses in a routine laboratory setting - improved sensitivity and specificity of PCR and sequence analysis compared to direct hybridisation Clin Chem Lab Med 2003, 41:787-791. 12880142 10.1515/CCLM.2003.119
40. Sastre-Garau X Cartier I Jourdan-Da Silva N De Cremoux P Lepage V Charron D Regression of low-grade cervical intraepithelial neoplasia in patients with HLA-DRB1*13 genotype Obstet Gynecol 2004, 104:751-755. 15458897
41. Winer RL Kiviat NB Hughes JP et al Development and duration of human papillomavirus lesions, after initial infection J Infect Dis 2005, 191:731-738. 15688287 10.1086/427557
42. Insinga RP Dasbach EJ Elbasha EH Liaw KL Barr E Incidence and duration of cervical human papillomavirus 6, 11, 16 and 18 infections in young women: An evaluation from multiple analytic perspectives Cancer Epidemiol Biomarkers Prev 2007, 16:709-715. 17416761 10.1158/ 1055-9965.EPI-06-0846
43. Insinga RP Dasbach EJ Elbasha EH Liaw KL Barr E Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women Infect Agent Cancer 2007, 2:15. 17626624 10.1186/1750-9378-2-15 2034372
44. Holmes J Hemmett L Garfield S The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies Eur J Health Econ 2005, 6:30-37. 15682286 10.1007/ s10198-004-0254-1 1388082
45. Brown DR Shew ML Qadadri B et al A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women J Infect Dis 2005, 191:182-192. 15609227 10.1086/426867 2586143
46. Giuliano AR Harris R Sedjo RL et al Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study J Infect Dis 2002, 186:462-469. 12195372 10.1086/341782
47. Insinga RP Glass AG Rush BB Pap screening in a U.S. health plan Cancer Epidemiol Biomarkers Prev 2004, 13:355-360. 15006908
48. Mikhail MS Merkatz IR Romney SL Clinical usefulness of computerized colposcopy: Image analysis and conservative management of mild dysplasia Obstet Gynecol 1992, 80:5-8. 1603496
49. Kataja V Syrjanen K Mantyjarvi R et al Prospective follow-up of cervical HPV infections: Life table analysis of histopathological, cytological and colposcopic data Eur J Epidemiol 1989, 5:1-7. 2540024 10.1007/ BF00145037
50. Molano M Van den BA Plummer M et al Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: A population-based, 5-year follow-up study Am J Epidemiol 2003, 158:486-494. 12936904 10.1093/aje/kwg171
51. Syrjanen S Shabalova I Petrovichev N et al Age-specific incidence and clearance of high-risk human papillomavirus infections in women in the former Soviet Union Int J STD AIDS 2005, 16:217-223. 15835076 10.1258/ 0956462053420211
52. Konno R Paez C Sato S Yajima A Fukao A HPV, histologic grade and age. Risk factors for the progression of cervical intraepithelial neoplasia J Reprod Med 1998, 43:561-566. 9693405
53. Hoyer H Scheungraber C Kuehne-Heid R et al Cumulative 5-year diagnoses of CIN2, CIN3 or cervical cancer after concurrent high-risk HPV and cytology testing in a primary screening setting Int J Cancer 2005, 116:136-143. 15756677 10.1002/ijc.20955
54. Schneider A Hoyer H Lotz B et al Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy Int J Cancer 2000, 89:529-534. 11102899 10.1002/1097-0215(20001120)89:6<529::AID-IJC11>3.0.CO;2-G
55. Woodman CB Collins S Winter H et al Natural history of cervical human papillomavirus infection in young women: A longitudinal cohort study Lancet 2001, 357:1831-1836. 11410191 10.1016/S0140-6736(00)04956-4
56. Mao C Koutsky LA Ault KA et al Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: A randomized controlled trial Obstet Gynecol 2006, 107:18-27 16394035
57. Furber SE Weisberg E Simpson JM Progression and regression of low-grade epithelial abnormalities of the cervix Aust N Z J Obstet Gynaecol 1997, 37:107-112. 9075560 10.1111/j.1479-828X.1997.tb02230.x
58. Aoyama C Peters J Senadheera S Liu P Shimada H Uterine cervical dysplasia and cancer: Identification of c-myc status by quantitative polymerase chain reaction Diagn Mol Pathol 1998, 7:324-330. 10207671 10.1097/00019606-199812000-00006
59. Evans MF Mount SL Beatty BG Cooper K Biotinyl-tyramide-based in situ hybridization signal patterns distinguish human papillomavirus type and grade of cervical intraepithelial neoplasia Mod Pathol 2002, 15:1339-1347. 12481016 10.1038/modpathol.3880698
60. Isacson C Kessis TD Hedrick L Cho KR Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type Cancer Res 1996, 56:669-674. 8630992
61. Quade BJ Park JJ Crum CP Sun D Dutta A In vivo cyclin E expression as a marker for early cervical neoplasia Mod Pathol 1998, 11:1238-1246. 9872657
62. Shroyer KR Lovelace GS Abarca ML et al Detection of human papillomavirus DNA by in situ hybridization and polymerase chain reaction in human papillomavirus equivocal and dysplastic cervical biopsies Hum Pathol 1993, 24:1012-1016. 8253456 10.1016/0046-8177(93)90117-Y
63. Shi L Sings HL Bryan JT et al GARDASIL: Prophylactic human papillomavirus vaccine development - from bench top to bed-side Clin Pharmacol Ther 2007, 81:259-264. 17259949 10.1038/sj.clpt.6100055
64. Munoz N Bosch FX de Sanjose S et al Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 2003, 348:518-527. 12571259 10.1056/NEJMoa021641
65. De Aloysio D Miliffi L Iannicelli T Penacchioni P Bottiglioni F Intramuscular interferon-beta treatment of cervical intraepithelial neoplasia II associated with human papillomavirus infection Acta Obstet Gynecol Scand 1994, 73:420-424. 8009976 10.3109/00016349409006256
66. Benedet JL Bender H Jones H III Ngan HY Pecorelli S FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology Int J Gynaecol Obstet 2000, 70:209-262. 11041682 10.1016/S0020-7292(00)90001-8
67. Schiffman M Burk R Human Papillomaviruses Viral Infections of Humans New York, NY: Plenum Publishing Co Evans A, Kaslow R 4 1997:983-1023.
68. Westergaard L Norgaard M Severe cervical dysplasia. Control by biopsies or primary conization? A comparative study Acta Obstet Gynecol Scand 1981, 60:549-554. 7336893
69. SEER*Stat 6.1.4 - SEER Cancer Incidence Public-Use Database, 1973-2002. 4-25-0005 Bethesda, MD, U.S.A., Cancer Statistics Branch, National Cancer Institute, National Insititutes of Health
70. Gustafsson L Ponten J Bergstrom R Adami HO International incidence rates of invasive cervical cancer before cytological screening Int J Cancer 1997, 71:159-165. 9139836 10.1002/ (SICI)1097-0215(19970410)71:2<159::AID-IJC6>3.0.CO;2-#
71. Herrero R Castle PE Schiffman M et al Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica J Infect Dis 2005, 191:1796-1807. 15871111 10.1086/428850
72. Chesson HW Blandford JM Gift TL Tao G Irwin KL The estimated direct medical cost of sexually transmitted diseases among American youth, 2000 Perspect Sex Reprod Health; 2004, 36:11-19. 14982672 10.1363/3601104
73. Insinga RP Glass AG Rush BB Diagnoses and outcomes in cervical cancer screening: A population-based study Am J Obstet Gynecol 2004, 191:105-113. 15295350 10.1016/j.ajog.2004.01.043
74. Nygard JF Nygard M Skare GB Thoresen SO Screening histories of women with CIN 2/3 compared with women diagnosed with invasive cervical cancer: A retrospective analysis of the Norwegian Coordinated Cervical Cancer Screening Program Cancer Causes Control 2005, 16:463-474. 15953989 10.1007/s10552-004-6295-z
75. Laskey PW Meigs JW Flannery JT Uterine cervical carcinoma in Connecticut, 1935-1973: Evidence for two classes of invasive disease J Natl Cancer Inst 1976, 57:1037-1043. 1003540
76. Dorn HF Cutler SJ Morbidity from cancer in the United States Public Health Monogr 1959, 73:1-207.
77. Kessler II Cervical cancer epidemiology in historical perspective J Reprod Med 1974, 12:173-185. 4599289
78. Evans MF Mount SL Vacek PM Cooper K High-risk human papillomavirus type does not predict grade of cervical intraepithelial neoplasia Eur J Gynaecol Oncol 2003, 24:373-376. 14584647
79. Oktay MH Oktay K Hamele-Bena D Buyuk A Koss LG Focal adhesion kinase as a marker of malignant phenotype in breast and cervical carcinomas Hum Pathol 2003, 34:240-245. 12673558 10.1053/hupa.2003.40
80. Richardson H Kelsall G Tellier P et al The natural history of type-specific human papillomavirus infections in female university students Cancer Epidemiol Biomarkers Prev 2003, 12:485-490. 12814991
81. Villa LL Ault KA Giuliano AR et al Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18 Vaccine 2006, 24:5571-5583. 16753240 10.1016/ j.vaccine.2006.04.068
82. Koutsky LA Ault KA Wheeler CM et al A controlled trial of a human papillomavirus type 16 vaccine N Engl J Med 2002, 347:1645-1651. 12444178 10.1056/NEJMoa020586
83. Viscidi RP Schiffman M Hildesheim A et al Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: Results from a population-based study in Costa Rica Cancer Epidemiol Biomarkers Prev 2004, 13:324-327. 14973086 10.1158/ 1055-9965.EPI-03-0166
84. Af G V Kibur M Wang Z et al Stability over time of serum antibody levels to human papillomavirus type 16 J Infect Dis 1998, 177:1710-1714. 9607854 10.1086/517428
85. Matsumoto K Yasugi T Oki A et al IgG antibodies to HPV16, 52, 58 and 6 L1-capsids and spontaneous regression of cervical intraepithelial neoplasia Cancer Lett 2006, 231:309-313. 16399232 10.1016/ j.canlet.2005.02.023
86. Beutner KR Wiley DJ Douglas JM et al Genital warts and their treatment Clin Infect Dis 1999, 28(Suppl 1):S37-S56. 10028109 10.1086/514722
87. Wiley DJ Douglas J Beutner K et al External genital warts: Diagnosis, treatment, and prevention Clin Infect Dis 2002, 35:S210-S224. 12353208 10.1086/342109
88. Friedman-Kien A Management of condylomata acuminata with Alferon N injection, interferon alfa-n3 (human leukocyte derived) Am J Obstet Gynecol 1995, 172:1359-1368. 7726291 10.1016/0002-9378(95)90404-2
89. Wildman GM Tang A Have a nice day - do a wart audit Int J STD AIDS 2003, 14:710-711. 14596776 10.1258/095646203322387983
90. Ries L Eisner M Kosary C et al SEER cancer statistics review, 1975-2002 Bethesda, MD, National Cancer Institute 2005. http://seer.cancer.gov/csr/ 1975_2002/
91. Chen RJ Lin YH Chen CA Huang SC Chow SN Hsieh CY Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan Gynecol Oncol 1999, 73:184-190. 10329032 10.1006/gyno.1999.5364
92. Flores-Luna L Salazar-Martinez E Escudero-De los RP Gonzalez-Lira G Zamora-Munoz S Lazcano-Ponce E Prognostic factors related to cervical cancer survival in Mexican women Int J Gynaecol Obstet 2001, 75:33-42. 11597617 10.1016/S0020-7292(01)00471-4
93. Keshavarz H Hillis SD Kieke BA Marchbanks PA Hysterectomy surveillance-United States, 1994-1999 MMWR CDC Surveill Summ 2002, 51:1-8.
94. Redburn JC Murphy MF Hysterectomy prevalence and adjusted cervical and uterine cancer rates in England and Wales BJOG 2001, 108:388-395. 11305546 10.1016/S0306-5456(00)00098-X
95. Analysis of women's health care utilization in Taiwan - cesaerean section, hysterectomy, service-specific and group specific utilization rate.: Final report Taipei: Department of Health, Bureau of National Health Insurance 2004.
96. Fowles JB Fowler E Craft C McCoy CE Comparing claims data and self-reported data with the medical record for Pap smear rates Eval Health Prof 1997, 20:324-342. 10183327 10.1177/016327879702000305
97. Gordon NP Hiatt RA Lampert DI Concordance of self-reported data and medical record audit for six cancer screening procedures J Natl Cancer Inst 1993, 85:566-570. 8455203 10.1093/jnci/85.7.566
98. McGovern PG Lurie N Margolis KL Slater JS Accuracy of self-report of mammography and Pap smear in a low-income urban population Am J Prev Med 1998, 14:201-208. 9569221 10.1016/S0749-3797(97)00076-7
99. Newell S Girgis A Sanson-Fisher R Ireland M Accuracy of patients' recall of Pap and cholesterol screening Am J Public Health 2000, 90:1431-1435. 10983202 10.2105/AJPH.90.9.1431 1447635
100. Suarez L Goldman DA Weiss NS Validity of Pap smear and mammogram self-reports in a low-income Hispanic population Am J Prev Med 1995, 11:94-98. 7632456
101. Wallihan DB Stump TE Callahan CM Accuracy of self-reported health services use and patterns of care among urban older adults Med Care 1999, 37:662-670. 10424637 10.1097/00005650-199907000-00006
102. Chattopadhyay SK Ebrahim SH Tao G McKenna MT Use of cervical cancer screening among insured women: The extent of missed opportunities Health Policy 2005, 73:194-201. 15978962 10.1016/j.healthpol.2004.11.012
103. Sirovich BE Welch HG The frequency of Pap smear screening in the United States J Gen Intern Med 2004, 19:243-250. 15009779 10.1111/ j.1525-1497.2004.21107.x 1492158
104. Janerich DT Hadjimichael O Schwartz PE et al The screening histories of women with invasive cervical cancer, Connecticut Am J Public Health 1995, 85:791-794. 7762711 10.2105/AJPH.85.6.791 1615485
105. Sung HY Kearney KA Miller M Kinney W Sawaya GF Hiatt RA Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan Cancer 2000, 88:2283-2289. 10820350 10.1002/(SICI)1097-0142(20000515)88:10<2283::AID-CNCR12>3.0.CO;2-D
106. Insinga RP Glass AG Rush BB Response to "Use of cervical cancer screening among insured women: The extent of missed opportunities" [Health Policy 73 (2005) 194-201] Health Policy 2005. 16297495
107. Warnecke RB Sudman S Johnson TP O'Rourke D Davis AM Jobe JB Cognitive aspects of recalling and reporting health-related events: Papanicolaou smears, clinical breast examinations, and mammograms Am J Epidemiol 1997, 146:982-992. 9400341
108. Hewitt M Devesa SS Breen N Cervical cancer screening among U.S. women: analyses of the 2000 National Health Interview Survey Prev Med 2004, 39:270-278. 15226035 10.1016/j.ypmed.2004.03.035
109. Schootman M Jeffe DB Baker EA Walker MS Effect of area poverty rate on cancer screening across US communities J Epidemiol Community Health 2006, 60:202-207. 16476748 10.1136/jech.2005.041020 2465556
110. Cervical cancer screening program [2005/2006] National Health Service Cervical Screening Programme Statistics. Leeds, United Kingdom 2007 http://www.ic.nhs.uk/pubs/csp0506
111. Taiwan Pap Registry Annual Report, 2005 Bureau of Health Promotion, Department of Health, ROC 2005.
112. Louftalot M Avances del programa de detección oportuna del cáncer cervical en México Presented at the XI Congreso de Investigación en Salud Pública, Cuernavaca, Mexico 2005.
113. Saint M Gildengorin G Sawaya GF Current cervical neoplasia screening practices of obstetrician/gynecologists in the US Am J Obstet Gynecol 2005, 192:414-421. 15695980 10.1016/j.ajog.2004.09.026
114. Bigras G de Marval F The probability for a Pap test to be abnormal is directly proportional to HPV viral load: Results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13,842 women Br J Cancer 2005, 93:575-581. 16136031 10.1038/sj.bjc.6602728
115. Coste J Cochand-Priollet B De Cremoux P et al Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening BMJ 2003, 326:733. 12676841 10.1136/bmj.326.7392.733 152633
116. Cochand-Priollet B Le Gales C De Cremoux P et al Cost-effectiveness of monolayers and human papillomavirus testing compared to that of conventional Papanicolaou smears for cervical cancer screening: Protocol of the study of the French Society of Clinical Cytology Diagn Cytopathol 2001, 24:412-420. 11391824 10.1002/dc.1091
117. Mitchell MF Schottenfeld D Tortolero-Luna G Cantor SB Richards-Kortum R Colposcopy for the diagnosis of squamous intraepithelial lesions: A meta-analysis Obstet Gynecol 1998, 91:626-631. 9540955 10.1016/ S0029-7844(98)00006-4
118. Distefano AL Picconi MA Alonio LV et al Persistence of human papillomavirus DNA in cervical lesions after treatment with diathermic large loop excision Infect Dis Obstet Gynecol 1998, 6:214-219. 9894176 10.1002/(SICI)1098-0997(1998)6:5<214::AID-IDOG5>3.0.CO;2-I 1784810
119. Flannelly G Langhan H Jandial L Mana E Campbell M Kitchener H A study of treatment failures following large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia Br J Obstet Gynaecol 1997, 104:718-722. 9197876
120. Luesley DM Cullimore J Redman CW et al Loop diathermy excision of the cervical transformation zone in patients with abnormal cervical smears BMJ 1990, 300:1690-1693. 2264855 10.1136/bmj.300.6741.1690 1663301
121. Murdoch JB Morgan PR Lopes A Monaghan JM Histological incomplete excision of CIN after large loop excision of the transformation zone (LLETZ) merits careful follow up, not retreatment Br J Obstet Gynaecol 1992, 99:990-993. 1477023
122. Chen RJ Chang DY Yen ML Chow SN Huang SC Loop electrosurgical excision procedure for conization of the uterine cervix J Formos Med Assoc 1994, 93:196-199. 7920057
123. Goff BA Rice LW Fleischhacker DS Abu-Jawdeh GM Muntz HG Large loop excision of the transformation zone in patients with exocervical squamous intraepithelial lesions Eur J Gynaecol Oncol 1994, 15:257-262. 7957331
124. Wright TC Jr Gagnon S Richart RM Ferenczy A Treatment of cervical intraepithelial neoplasia using the loop electrosurgical excision procedure Obstet Gynecol 1992, 79:173-178. 1731281
125. Bekkers RL Melchers WJ Bakkers JM et al The role of genotype-specific human papillomavirus detection in diagnosing residual cervical intraepithelial neoplasia Int J Cancer 2002, 102:148-151. 12385010 10.1002/ijc.10691
126. Gardeil F Barry-Walsh C Prendiville W Clinch J Turner MJ Persistent intraepithelial neoplasia after excision for cervical intraepithelial neoplasia grade III Obstet Gynecol 1997, 89:419-422. 9052597 10.1016/ S0029-7844(96)00505-4
127. Cruickshank ME Sharp L Chambers G Smart L Murray G Persistent infection with human papillomavirus following the successful treatment of high grade cervical intraepithelial neoplasia BJOG 2002, 109:579-581. 12066952 10.1111/j.1471-0528.2002.01554.x
128. Paraskevaidis E Arbyn M Sotiriadis A et al The role of HPV DNA testing in the follow-up period after treatment for CIN: A systematic review of the literature Cancer Treat Rev 2004, 30:205-211. 15023438 10.1016/ j.ctrv.2003.07.008
129. Fen J Yoshinouchi M Nakamura K et al Eradication of HPV post-surgical treatments, its correlation with specific types, types of surgery and the physical status Oncol Rep 2004, 12:375-379. 15254705
130. Arany I Rady P Tyring SK Effect of interferon therapy on human papillomavirus copy number in patients with Condyloma acuminatum Am J Med Sci 1995, 310:14-18. 7541607 10.1097/00000441-199507000-00006
131. Syed TA Ahmadpour OA Ahmad SA Ahmad SH Management of female genital warts with an analog of imiquimod 2% in cream: A randomized, double-blind, placebo-controlled study J Dermatol 1998, 25:429-433. 9714974
132. Carey FM Quah SP Dinsmore W Maw RD Patient assessment of anogenital warts and the success of treatment with home applied therapy Int J STD AIDS 2004, 15:316-318. 15117500 10.1258/095646204323012797
133. Wiley DJ Grosser S Qi K et al Validity of self-reporting of episodes of external genital warts Clin Infect Dis 2002, 35:39-45. 12060873 10.1086/ 340743